Description Indications and Usage Mechanisms of Action Clinical Research Warnings and Precautions
ChemicalBook > CAS DataBase List > Dabigatran etexilate

Dabigatran etexilate

Description Indications and Usage Mechanisms of Action Clinical Research Warnings and Precautions
Product Name
Dabigatran etexilate
CAS No.
211915-06-9
Chemical Name
Dabigatran etexilate
Synonyms
DL-;BIBR-1048;N-[[2-[[[4-[[[(Hexyloxy)carbonyl]aMidino]iMinoMethyl]phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridyl-beta-alanine,ethyl ester;Etexilate;Dabigatran ester;BIBR-1048 (Dabigatran);N-[2-[4-[N-(Hexyloxycarbonyl)aMidino]phenylaMinoMethyl]-1-Methyl-1H-benziMidazol-5-ylcarbonyl]-N-(2-;CS-62;Prazaxa;BIBR 1048
CBNumber
CB62485052
Molecular Formula
C34H41N7O5
Formula Weight
627.73
MOL File
211915-06-9.mol
More
Less

Dabigatran etexilate Property

Melting point:
128-129°
Density 
1.24±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
9.88±0.46(Predicted)
form 
Solid
color 
White to Pale Yellow
Stability:
Hygroscopic
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
17131
Product name
Dabigatran etexilate
Purity
≥95%
Packaging
5mg
Price
$49
Updated
2024/03/01
Cayman Chemical
Product number
17131
Product name
Dabigatran etexilate
Purity
≥95%
Packaging
10mg
Price
$92
Updated
2024/03/01
Cayman Chemical
Product number
17131
Product name
Dabigatran etexilate
Purity
≥95%
Packaging
50mg
Price
$427
Updated
2024/03/01
TRC
Product number
D100140
Product name
DabigatranEtexilate
Packaging
500mg
Price
$165
Updated
2021/12/16
Biosynth Carbosynth
Product number
BD164344
Product name
Dabigatran etexilate
Packaging
50mg
Price
$243
Updated
2021/12/16
More
Less

Dabigatran etexilate Chemical Properties,Usage,Production

Description

Dabigatran etexilate (Pradaxa, BIBR 1048, Boehringer Ingelheim) is the prodrug of dabigatran (originally known as BIBR 953), a potent, nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.

Indications and Usage

Dabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease.

Mechanisms of Action

It achieves anticoagulant effects through specific and selective inhibition of blood enzymes (free or bound). After oral ingestion and absorption through the digestive system, Dabigatran turns into Dabiga groups that have the direct anticoagulant abilities. By binding to thrombin in fibrin specific binding sites, Dabigatran stops fibrinogen from cleaving into fibrin, thus interrupting the blood clotting network and consequently thrombosis. Dabiga groups can also dissociate from the fibrin-thrombin coagulate and have an anticoagulating effect. Different from vitamin K antagonists, which affect different coagulants, Dabigatran can provide effective, predictable and stable anticoagulant effects. It will also have minimal reactions to other drugs or food, and does not require frequent monitoring or dosage adjustment.

Clinical Research

Compared to the control group treated with Warfarin, Dabigatran can significantly decrease the risk of stroke and embolic disease (including hemorrhagic stroke), greatly reduce the occurrence of bleeding (including fatal bleeding and intracranial hemorrhage), and greatly lower vascular mortality rate. Dabigatran provides effective and stable anticoagulant effects and does not require constant monitoring of anticoagulant functions or dosage adjustments.

Warnings and Precautions

1. Dabigatran is not to be used by patients with severe kidney damage (CrCl<30ml/min).
2. Patients with high bleeding risk should also not use Dabigatran.
3. Patients must be tested and monitored for signs of lack of bleeding or anemia; if there is severe bleeding, cease use of Dabigatran and identify the bleeding area.
4. Dabigatran is not suitable for patients with significant manifestations of rheumatic valvar heart disease or patients with artificial heart valves.

Description

Dabigatran etexilate is an orally administered pro-drug of dabigatran, which is a direct inhibitor of thrombin and a potent anticoagulant. The serine protease thrombin is the final mediator in the coagulation cascade that leads to the production of fibrin, the main protein component of blood clots. Thrombin is also a potent activator of platelets. Consequently, thrombin inhibitors have found utility as anticoagulants in treating arterial and venous thrombosis. Warfarin, although orally available, has a narrow therapeutic index and requires frequent monitoring and dosage adjustment. Low-molecular-weight heparins provide better safety profile and less inter-patient variability; however, these agents are only available for parenteral administration. Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that act by directly binding to thrombin at its catalytic or fibrinogen-binding sites, or both. Unlike the heparins, DTIs do not require the activation of secondary factors such as antithrombin to derive their activity, which makes their action more predictable. In addition, their ability to inhibit both free and clot-bound thrombin predisposes them for enhanced anticoagulation effect.

Originator

Boehringer Ingelheim (Germany)

Uses

Dabigatran Etexilate is an oral anticoagulant and direct thrombin inhibitor.

Uses

BIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner sin

Definition

ChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.

brand name

Pradaxa

Synthesis

The chemical synthesis of dabigatran etexilate starts with the acylation of ethyl 3-(2-pyridylamino)propionate with 4-(methylamino)-3-nitrobenzoyl chloride to produce the corresponding amide. Subsequent reduction of the nitro group by catalytic hydrogenation, and cyclization of the resultant phenylenediamine with N-(4-cyanophenyl)glycine leads to a benzimidazole intermediate. The cyano group is then transformed into an amidine by employing the Pinner reaction. Finally, acylation of the amidino group with hexyl chloroformate gives rise to dabigatran etexilate.

in vitro

dabigatran showed anticoagulant effects in a concentration-dependent manner. it doubled the activated partrial thromboplastin time, prothrombin time and ecarin clotting in human ppp. [1]

Drug interactions

Potentially hazardous interactions with other drugs
Analgesics: possible increased risk of bleeding with NSAID’s; increased risk of haemorrhage with ketorolac or IV diclofenac - avoid.
Anti-arrhythmics: concentration increased by amiodarone, reduce dose of dabigatran; concentration increased by dronedarone - avoid.
Antibacterials: concentration reduced by rifampicin - avoid; possibly increased risk of bleeding with clarithromycin.
Anticoagulants: increased risk of haemorrhage with other anticoagulants - avoid.
Antidepressants: possible increased risk of bleeding with SSRIs; concentration possibly reduced by St John’s wort - avoid.
Antifungals: concentration increased by ketoconazole and possibly itraconazole - avoid
Ciclosporin: concentration possibly increased by ciclosporin - avoid.
Sulfinpyrazone: possible increased risk of bleeding.
Tacolimus: concentration possibly increased by tacrolimus - avoid.
Ticagrelor: concentration of dabigatran increased.
Verapamil: reduce dose of dabigatran to 150 mg daily, 75 mg in GFR=30-50mL/min.

Metabolism

Dabigatran etexilate is a prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma.
Mainly excreted in the urine (85%) and 6% via the faeces.

References

1. wienen w, stassen jm, priepke h et al. in-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. thromb haemost. 2007 jul;98(1):155-62.2. connolly sj, ezekowitz md, yusuf s et al. dabigatran versus warfarin in patients with atrialfibrillation. n engl j med. 2009 sep 17;361(12):1139-51.

Dabigatran etexilate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Dabigatran etexilate Suppliers

Kaifeng Mingren Pharmaceutical Co.,LTD
Tel
0371-65741762
Fax
QQ:2860768577
Email
sales@hasunny.com
Country
China
ProdList
2380
Advantage
58
Guangzhou Dreampharm Biotechnology Co., Ltd.
Tel
17825480238
Fax
QQ 3008233717
Email
3008233717@qq.com
Country
China
ProdList
9844
Advantage
12
Fuyang Sineva Pharmaceutical Co., Ltd
Tel
0558-2919017; 13866224493
Email
dingzhikui@sineva.com.cn
Country
China
ProdList
35
Advantage
58
Nanjing Shanyao Kangcheng biomedical Co., Ltd.
Tel
15722982350
Email
1170703875@qq.com
Country
China
ProdList
516
Advantage
58
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6011
Advantage
61
BeiJing Hwrk Chemicals Limted
Tel
0757-86329057 18501085097
Fax
010-89508210
Email
sales3.gd@hwrkchemical.com
Country
China
ProdList
7583
Advantage
55
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44751
Advantage
61
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9984
Advantage
60
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9551
Advantage
66
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
zhangsn@titansci.com
Country
China
ProdList
14113
Advantage
59
More
Less

View Lastest Price from Dabigatran etexilate manufacturers

Sinoway Industrial co., ltd.
Product
Dabigatran Etexilate 211915-06-9
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
99% up, High Density
Supply Ability
20 tons
Release date
2022-08-09
Hebei Mingeng Biotechnology Co., Ltd
Product
Dabigatran Etexilate 211915-06-9
Price
US $200.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
1000kg/Months
Release date
2022-11-20
henan kanbei chemical co.,ltd
Product
Dabigatran etexilate 211915-06-9
Price
US $0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
1000kg
Release date
2022-09-26

211915-06-9, Dabigatran etexilateRelated Search:


  • N-[[2-[[[4-[[[(Hexyloxy)carbonyl]aMidino]iMinoMethyl]phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridyl-beta-alanine,ethyl ester
  • Pradaxa (dabigatran)
  • Dabigatran Etexilate (free base)
  • Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]aMino]iMinoMethyl]phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester
  • BIBR-1048(Dabigatran etexilate)
  • N-[2-[4-[N-(Hexyloxycarbonyl)aMidino]phenylaMinoMethyl]-1-Methyl-1H-benziMidazol-5-ylcarbonyl]-N-(2-
  • BIBR 1048
  • BIBR-1048
  • Prazaxa
  • Dabigatran etexilate (Dabigatran etexilate methanesulfonate)
  • (E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
  • BIBR-1048, >=99%
  • Ethyl 3-(2-((4-(N-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl
  • 1-methyl-2-[N-[4-(-n-hexyloxycarbonylamidino) phenyl]aminomethyl]benzimidazol-5-yl- carboxylicacid-N-(2-pyridyl)-N- (2-ethoxycarbonylethyl)amide
  • N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-(2-pyridyl)-beta-alanine ethyl ester(Dabigatran etexilate)
  • Ethyl 3-(((2-(((4-((((hexyloxy) carbonyl) amino) iminomethyl) phenyl) amino)\methyl)-1-methyl-1H-benzimidazol-5-yl)\carbonyl)(pyridin-2-yl)amino) propanoate
  • Dabigatran etexilate
  • N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1H-benzimidazol-5-ylcarbonyl]-N-(2-pyridyl)-beta-alanine ethyl ester
  • phenolsulphophthaleine sodium salt
  • PR sodium salt
  • Etexilate
  • Dabigatran Etexilatr
  • BIBR-1048 (Dabigatran)
  • CS-62
  • BIBR 1048; DABIGATRAN ETEXILATE;BIBR1048
  • Dabigatran Free Base
  • abigatranetexilate
  • Ethyl 3-[2-[[[4-[N-[(Hexyloxy)carbonyl]carbamimidoyl]phenyl]amino]methyl]-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidaz
  • Ethyl N-[[2-[[4-[N-[(Hexyloxy)carbonyl]carbamimidoyl]anilino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alaninate
  • Dabigatran etexilate USP/EP/BP
  • Hexyl 2-(4-(((5-((3-ethoxy-3-oxopropyl)(pyridin-2-yl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)benzylidene)hydrazinecarboxylate
  • Dabigatran ester
  • Ethyl 3-(((2-(((4-(((( hexyloxy)carbonyl)amino)iminomethyl)pheny l)amino)methyl)-1-methy-lH-benzimidazole-5- yl)carbonyl)(pyridin-2-yl)amino)propanoate/
  • N-[2-[4-[N-(Hexyloxycarbonyl)amidino]phenylaminomethyl]-1-me...
  • Dabigatran etexilate impurity1516
  • Dabigatran EtexilateQ: What is Dabigatran Etexilate Q: What is the CAS Number of Dabigatran Etexilate Q: What is the storage condition of Dabigatran Etexilate Q: What are the applications of Dabigatran Etexilate
  • DL-
  • N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-Alanine, ethyl ester
  • Dabigatran etexilate (Mesylat)
  • ethyl 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
  • β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester
  • DBG-3A/DBG-3 (DABIGATRAN IMPURITY)
  • DABIGATRAN ETEXILATE 35%, 40.0%, 43%, 50% W/W PELLETS
  • Dabigatran Etexilate N-[[2-[[[4- [[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methy l]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β- Alanine Ethyl Ester
  • Dabigatran P-1
  • Dabigatran (BIBR-1048) etexilate
  • 211915-06-9
  • C34H41N7O5
  • Pharmaceutical intermediate
  • API
  • Dabigatran etexilate
  • Other APIs